Deleterious mutations of the BRCA1 and BRCA2 genes are a major risk factor for the development of breast and ovarian cancers.1–4 Mutation tests for these two genes commonly are now offered in specialised clinics.5,6 As a result, a large number of women with personal or family histories of breast or ovarian cancer seek genetic counselling. Accurate evaluation of the probability that a woman carries a germline pathogenic mutation at BRCA1 or BRCA2 therefore is essential to help counsellors and those being counselled to decide whether testing is appropriate. In this context, the questions of practical interest are: Given the pedigree, what is the chance of a mutation being present? and What is the chance of the DNA laboratory finding a mutatio...
The presence of a germline BRCA1/2 mutation improves options for tailored risk-reducing strategies a...
One of the most significant risk factors for the development of ovarian cancer (OC) is a genetic mut...
Women who carry a pathogenic mutation in the breast cancer susceptibility genes BRCA1 or BRCA2 (BRCA...
Deleterious mutations of the BRCA1 and BRCA2 genes are a major risk factor for the development of br...
eleterious mutations of the BRCA1 and BRCA2 genes are a major risk factor for the development of bre...
BRCA1 and BRCA2 mutation carriers have a very highlifetime risk for breast or ovarian cancer. Becaus...
We prospectively screened a hospital-based population of 1000 successive breast cancer patients rece...
Identifying germline BRCA pathogenic mutations in patients with ovarian or breast cancer is a crucia...
Identifying germline BRCA pathogenic mutations in patients with ovarian or breast cancer is a crucia...
The Department of Defense Familial Breast/Ovarian Cancer Research Project has offered genetic counse...
For genetic counselling of a woman on familial breast cancer, an accurate evaluation of the probabil...
Background: Because BRCA gene mutation testing is costly, occasionally uninformative, and frequently...
Objectives: To evaluate the accuracy of algorithms for predicting BRCAI/2 germ-line mutation carrier...
Objectives: Genetic testing for the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 h...
A mutation in the BRCA1 gene may confer substantial risk for breast and/or ovarian cancer. However, ...
The presence of a germline BRCA1/2 mutation improves options for tailored risk-reducing strategies a...
One of the most significant risk factors for the development of ovarian cancer (OC) is a genetic mut...
Women who carry a pathogenic mutation in the breast cancer susceptibility genes BRCA1 or BRCA2 (BRCA...
Deleterious mutations of the BRCA1 and BRCA2 genes are a major risk factor for the development of br...
eleterious mutations of the BRCA1 and BRCA2 genes are a major risk factor for the development of bre...
BRCA1 and BRCA2 mutation carriers have a very highlifetime risk for breast or ovarian cancer. Becaus...
We prospectively screened a hospital-based population of 1000 successive breast cancer patients rece...
Identifying germline BRCA pathogenic mutations in patients with ovarian or breast cancer is a crucia...
Identifying germline BRCA pathogenic mutations in patients with ovarian or breast cancer is a crucia...
The Department of Defense Familial Breast/Ovarian Cancer Research Project has offered genetic counse...
For genetic counselling of a woman on familial breast cancer, an accurate evaluation of the probabil...
Background: Because BRCA gene mutation testing is costly, occasionally uninformative, and frequently...
Objectives: To evaluate the accuracy of algorithms for predicting BRCAI/2 germ-line mutation carrier...
Objectives: Genetic testing for the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 h...
A mutation in the BRCA1 gene may confer substantial risk for breast and/or ovarian cancer. However, ...
The presence of a germline BRCA1/2 mutation improves options for tailored risk-reducing strategies a...
One of the most significant risk factors for the development of ovarian cancer (OC) is a genetic mut...
Women who carry a pathogenic mutation in the breast cancer susceptibility genes BRCA1 or BRCA2 (BRCA...